Alnylam soars past $50B market cap
The Boston Business Journal's Power 50, "The Movement Makers," focuses on those in the Boston-area business community who demonstrate the most influence on making both their company and the region a better place for everyone in it.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
3 minutes ago
- USA Today
WNBA-to-Boston celebrations premature? League pushes back on CT Sun move after Pagliuca deal
Fans celebrating the arrival of the WNBA to the City of Boston might want to temper their expectations in the short term. Recent reporting from the Boston Globe's Gary Washburn relates that the WNBA itself is throwing cold water on ta potential move of the recently-purchased Connecticut Sun to a new location. Former Boston Celtics minority owner and Bain Capital executive Steve Pagliuca recently purchased the team for a record $325 million, with another $100 million earmarked to build a dedicated practice facility for the team in Boston. But per Washburn, after news of the sale broke this week, the league sent the reporter a release pushing back on a potential move out of the Nutmeg state. "Relocation decisions are made by the WNBA Board of Governors and not by individual teams," related the WNBA to Washburn, also noting that "no groups from Boston applied for a team." This could put a bit of a damper on things, given Pagliuca would be one of the first names for an expansion team in the area, yet the former Celtics owner now finds himself the new owner (pending league approval) of a team the WNBA appears determined to keep in Connecticut. "Nine additional cities also applied for WNBA teams and remain under active consideration. Those other cities remain under consideration based on the extensive work they did as part of the expansion process and currently have priority over Boston," added the league. This course of action may have actually put the city behind the proverbial eight ball, as the WNBA may be looking to avoid following in the footsteps of the NBA with the highly unpopular move of the Seattle SuperSonics to Oklahoma City in the aughts. Interestingly, the release tendered to Washburn also notes that a "prospective Celtics owner has also reached out to the league office and asked that Boston receive strong consideration for a WNBA franchise at the appropriate time." Does this mean the ownership group helmed by Bill Chisholm currently in the process of securing final NBA approval to buy the Boston-based NBA ball club is also the leading group to secure a WNBA team in the same city? At present, details on all of the above are murky, but will likely continue to develop in the coming weeks. Listen to "Havlicek Stole the Pod" on: Spotify: iTunes: YouTube:
Yahoo
3 hours ago
- Yahoo
What To Expect From Vertex Pharmaceuticals's (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here's what to look for. Vertex Pharmaceuticals missed analysts' revenue expectations by 2.3% last quarter, reporting revenues of $2.77 billion, up 3% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance slightly missing analysts' expectations. Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Vertex Pharmaceuticals's revenue to grow 9.8% year on year to $2.90 billion, improving from the 6.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street's revenue estimates three times over the last two years. Looking at Vertex Pharmaceuticals's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Vertex Pharmaceuticals's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $505.19 (compared to the current share price of $464). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
The 5 cities where home prices are dropping fast as the housing freeze causes inventory to pile up
Home prices are dropping in a handful of major US cities, creating opportunities for buyers. A stuck housing market is causing inventory to pile up, putting pressure on prices. Home prices are elevated nationally, but these five markets are seeing declines. The housing market is still frozen over. While that hasn't translated into meaningful price declines nationally, there are a handful of areas where things look better for home buyers. Shop Top Mortgage Rates A quicker path to financial freedom Your Path to Homeownership Personalized rates in minutes Redfin site said the median sales price for a home dropped in 14 of the 50 most populous US metro areas in the last month. That's largely due to the uncertainty hanging over the US economy, which is causing inventory to pile up in the market, Redfin said in its report. "Sellers need to start coming to terms with two things: One, homes are more often going to sit on the market for longer than a week or two before they sell, and two, buyers are gaining the upper hand," James Gulden, a Redfin agent based in Boston, said in a statement. The median home prices notched an all-time high in June, touching $435,300, but some areas cooled in July. Here are the top five cities that saw the steepest drop in median home sales prices in the four weeks leading up to July 27, according to Redfin. 1. Oakland, California Median sale price: $850,000 (June 2025) YoY% drop in four-week period: -6.8% 2. West Palm Beach, Florida Median sale price: $425,000 (June 2025) YoY% drop in four-week period: -4.9% 3. Jacksonville, Florida Median sale price: $300,990 (June 2025) YoY% drop in four-week period: -3.1% 4. Austin, Texas Median sale price: $556,340 (June 2025) YoY% drop in four-week period: -2.9% 5. Houston, Texas Median sale price: $369,000 (June 2025) YoY% drop in four-week period: -2.8% Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
